Business Wire

NY-WEBBING

5.4.2022 14:03:04 CEST | Business Wire | Press release

Share
New WebbingCTRL Provides Enterprises with Complete, Zero-Touch Global IoT Control over Carrier Connectivity

Webbing , a global MVNO (Mobile Virtual Network Operator) connectivity provider for enterprise mobility and IoT, today announced the immediate availability of WebbingCTRL , a fast and simple global-ready connectivity solution. WebbingCTRL is the only SIM in the world that can easily and remotely become any wireless carrier’s SIM, eliminating network provider lock-in and providing complete control over connectivity with zero-touch provisioning.

IoT connectivity can require substantial costs and time to orchestrate the implementation of network providers. Additionally, IoT use cases are rapidly changing, so organizations need a way to make future-proof decisions today in order to handle connectivity challenges on the horizon. Using the WebbingCTRL platform, organizations can easily add, remove, and swap the carrier for any number of IoT or enterprise deployments to another wireless carrier of their choice with which they have an eSIM subscription. There’s no need for carrier integration.

The IoT environment is accelerating, and connectivity solutions need to adapt to fast-moving deployments now and in the future. The WebbingCTRL eSIM delivers total flexibility to ensure devices have reliable connectivity, anywhere in the world. The ability to remotely provision devices without extra carrier integration or collaboration also vastly reduces time-consuming deployment cycles and could have a huge impact on the ability to scale.

The WebbingCTRL solution eSIM is device agnostic and comes in any form factor. As a result, businesses can gain complete control over connectivity for a wide array of use cases, including:

  • Enterprise employee mobile connectivity: Enables organizations to provide seamless connectivity for employees as they cross national boundaries and enter areas where one carrier may have better coverage than another.
  • Transportation and logistics : Enable IoT tracking devices to switch automatically from a private network in a warehouse to a public network when in transit.
  • Mission-critical IoT: Prevent interruption to operations that depend on connectivity when one carrier’s coverage is down by switching automatically to another.
  • Automotive: Connected vehicles need constant connectivity and they cannot always use a roaming carrier due to regional connectivity regulations. WebbingCTRL can automatically change carriers as vehicles cross into new coverage areas or national borders.

“With WebbingCTRL, companies can finally take complete control of their connectivity to ensure business continuity, take advantage of better pricing and coverage and avoid having to physically touch hundreds, even thousands of devices to change carriers,” said Noam Lando, co-founder and CEO at Webbing. “Companies can securely control all their devices’ connectivity, with the confidence to connect anywhere in the world, 24-7, both now and in the future.”

Because WebbingCTRL works independently of SM-DP and SM-SR infrastructure, the carrier change takes place almost immediately, and the eSIM will act just as if the SIM card had been physically changed to the new carrier. And WebbingCTRL is not limited to public networks but can also be used to manage connectivity to private networks.

Additionally, companies can set up business rules that will automatically change the carrier under specific conditions, such as location, country, loss of connectivity or even after a certain amount of time.

For more information about WebbingCTRL and ways to streamline your IoT deployment, contact sales@iamwebbing.com .

About Webbing

Webbing is a global data MVNO that delivers innovative enterprise grade, global connectivity and IoT services. Our secured network of 600+ mobile carriers across more than 200 countries, ensures superior data connectivity between businesses, people, and things wherever the device is located.

Since our foundation in 2010, we have been developing revolutionary SIM technology, powerful management platforms and a robust global network that revolutionize your data, making it relevant and actionable. Our leading-edge solutions deliver a streamlined, centralized, and scalable means of deploying and managing organizations' global fleet of devices. Our experts assist in every step of the device on boarding process to ensure you are set up to meet your organization’s connectivity needs. For more information, visit https://www.webbingsolutions.com/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye